Please ensure Javascript is enabled for purposes of website accessibility

The Gory Details on Edwards Lifesciences's Double Miss

By Seth Jayson - Updated Apr 10, 2017 at 1:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Just the facts, Fool.

Edwards Lifesciences (NYSE: EW) reported earnings on April 23. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Edwards Lifesciences missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.

Margins expanded across the board.

Revenue details
Edwards Lifesciences notched revenue of $496.7 million. The 22 analysts polled by S&P Capital IQ looked for a top line of $518.7 million on the same basis. GAAP reported sales were 8.2% higher than the prior-year quarter's $459.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.72. The 25 earnings estimates compiled by S&P Capital IQ averaged $0.76 per share. Non-GAAP EPS of $0.72 for Q1 were 36% higher than the prior-year quarter's $0.53 per share. GAAP EPS of $1.24 for Q1 were 125% higher than the prior-year quarter's $0.55 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 75.4%, 310 basis points better than the prior-year quarter. Operating margin was 22.0%, 320 basis points better than the prior-year quarter. Net margin was 29.2%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $535.8 million. On the bottom line, the average EPS estimate is $0.81.

Next year's average estimate for revenue is $2.14 billion. The average EPS estimate is $3.28.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 148 members out of 201 rating the stock outperform, and 53 members rating it underperform. Among 60 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give Edwards Lifesciences a green thumbs-up, and 16 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $98.40.

Is Edwards Lifesciences the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Edwards Lifesciences Corporation Stock Quote
Edwards Lifesciences Corporation
EW
$96.13 (1.92%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.